Royalty Pharma | Sustainability Performance
Invests in and manages pharmaceutical royalties and intellectual property. Activities include acquiring rights to drug products, monitoring revenue streams, and managing legal and regulatory obligations, while providing capital to support ongoing development projects.
1996
United States
51 - 200 employees
Biotechnology
$1B - 10B in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#8765
Overallⓘ#2015
in United Statesⓘ#205
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Leading
Controversy level
- Royalty Pharma plc, US/Dublin pharma royalty investment major, has faced multiple US shareholder class actions over alleged inadequate disclosure of multiple biotech royalty investment customer concentration risks affecting Royalty Pharma's share price, plus periodic SEC enforcement scrutiny on alleged inadequate disclosure of competitive market displacement affecting US institutional shareholders.
